• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纳米技术在三阴性乳腺癌治疗中的应用:全面综述。

Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review.

机构信息

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research Mohali, S.A.S Nagar, Punjab 160062, India.

Northern Railway Hospital, Sri Mata Vaishno Devi, Katra, Reasi 182320, India.

出版信息

Curr Drug Metab. 2022;23(10):781-799. doi: 10.2174/1389200223666220608144551.

DOI:10.2174/1389200223666220608144551
PMID:35676850
Abstract

Breast cancer is the most prevalent cancer in women around the world, having a sudden spread nowadays because of the poor sedentary lifestyle of people. Comprising several subtypes, one of the most dangerous and aggressive ones is triple-negative breast cancer or TNBC. Even though conventional surgical approaches like single and double mastectomy and preventive chemotherapeutic approaches are available, they are not selective to cancer cells and are only for symptomatic treatment. A new branch called nanotechnology has emerged in the last few decades that offers various novel characteristics, such as size in nanometric scale, enhanced adherence to multiple targeting moieties, active and passive targeting, controlled release, and site-specific targeting. Among various nanotherapeutic approaches like dendrimers, lipid-structured nanocarriers, carbon nanotubes, etc., nanoparticle targeted therapeutics can be termed the best among all for their specific cytotoxicity to cancer cells and increased bioavailability to a target site. This review focuses on the types and molecular pathways involving TNBC, existing treatment strategies, various nanotechnological approaches like exosomes, carbon nanotubes, dendrimers, lipid, and carbon-based nanocarriers, and especially various nanoparticles (NPs) like polymeric, photodynamic, peptide conjugated, antibody-conjugated, metallic, inorganic, natural product capped, and CRISPR based nanoparticles already approved for treatment or are under clinical and pre-clinical trials for TNBC.

摘要

乳腺癌是全球女性最常见的癌症,由于人们不良的久坐生活方式,其发病率如今突然上升。乳腺癌有多个亚型,其中最危险和侵袭性的一种是三阴性乳腺癌(TNBC)。尽管有传统的手术方法,如单切术和双切术,以及预防性化疗方法,但这些方法对癌细胞没有选择性,只是对症治疗。在过去几十年中,一个名为纳米技术的新分支出现了,它提供了各种新颖的特性,如纳米级的尺寸、增强对多种靶向部分的黏附性、主动和被动靶向、控制释放和特定部位靶向。在各种纳米治疗方法中,如树状聚合物、脂质结构纳米载体、碳纳米管等,纳米颗粒靶向治疗可以被称为所有方法中最好的方法,因为它对癌细胞具有特异性细胞毒性,并且增加了对靶部位的生物利用度。这篇综述重点介绍了涉及 TNBC 的类型和分子途径、现有的治疗策略、各种纳米技术方法,如外泌体、碳纳米管、树状聚合物、脂质和基于碳的纳米载体,以及特别是各种已经批准用于治疗 TNBC 或正在进行临床试验或临床前试验的纳米颗粒(NPs),如聚合物、光动力、肽偶联、抗体偶联、金属、无机、天然产物帽、基于 CRISPR 的 NPs。

相似文献

1
Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review.纳米技术在三阴性乳腺癌治疗中的应用:全面综述。
Curr Drug Metab. 2022;23(10):781-799. doi: 10.2174/1389200223666220608144551.
2
Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple- Negative Breast Cancer (TNBC).纳米技术在三阴性乳腺癌(TNBC)诊断和治疗中的最新进展。
Curr Pharm Biotechnol. 2022;23(13):1581-1595. doi: 10.2174/1389201023666211230113658.
3
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.基于纳米技术的乳腺癌和三阴性乳腺癌治疗方法的综述。
J Control Release. 2020 Oct 10;326:628-647. doi: 10.1016/j.jconrel.2020.07.003. Epub 2020 Jul 10.
4
Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer.基于纳米技术的 siRNA 递药策略治疗三阴性乳腺癌。
Int J Pharm. 2021 Aug 10;605:120835. doi: 10.1016/j.ijpharm.2021.120835. Epub 2021 Jun 28.
5
Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer.树状聚合物作为多功能纳米载体治疗乳腺癌的最新进展。
Eur J Pharm Sci. 2021 Sep 1;164:105890. doi: 10.1016/j.ejps.2021.105890. Epub 2021 Jun 1.
6
Recent Advances in Nanotechnology-Based Targeted Therapeutics for Breast Cancer Management.基于纳米技术的乳腺癌靶向治疗的最新进展
Curr Drug Metab. 2022;23(8):587-602. doi: 10.2174/1389200223666220514151110.
7
Nanosoldiers: A promising strategy to combat triple negative breast cancer.纳米战士:攻克三阴性乳腺癌的有前途策略。
Biomed Pharmacother. 2019 Feb;110:319-341. doi: 10.1016/j.biopha.2018.11.122. Epub 2018 Dec 4.
8
Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.靶向三阴性乳腺癌的 EGFR 可增强紫杉醇和西妥昔单抗偶联纳米金刚石纳米复合材料的治疗效果。
Acta Biomater. 2019 Mar 1;86:395-405. doi: 10.1016/j.actbio.2019.01.025. Epub 2019 Jan 16.
9
Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.脂质共轭雌激素衍生物的脂质纳米载体抑制肿瘤生长并增强顺铂对三阴性乳腺癌的活性:药代动力学和疗效评估。
Mol Pharm. 2015 Apr 6;12(4):1105-20. doi: 10.1021/mp5008629. Epub 2015 Mar 2.
10
Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.负载氨基黄酮的表皮生长因子受体靶向单分子胶束纳米颗粒在三阴性乳腺癌中显示出抗癌作用。
Biomaterials. 2016 Sep;101:20-31. doi: 10.1016/j.biomaterials.2016.05.041. Epub 2016 May 27.

引用本文的文献

1
Short- and long-term efficacy of olaparib combined with chemotherapy in advanced triple-negative breast cancer.奥拉帕利联合化疗治疗晚期三阴性乳腺癌的短期和长期疗效
Am J Cancer Res. 2025 Jul 15;15(7):3197-3208. doi: 10.62347/GCGE6470. eCollection 2025.
2
Microenvironment and Tumor Heterogeneity as Pharmacological Targets in Precision Oncology.微环境与肿瘤异质性作为精准肿瘤学中的药理学靶点
Pharmaceuticals (Basel). 2025 Jun 18;18(6):915. doi: 10.3390/ph18060915.
3
Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy.

本文引用的文献

1
Hyaluronic acid-coated and Olaparib-loaded PEI - PLGA nanoparticles for the targeted therapy of triple negative breast cancer.透明质酸包覆奥拉帕利载聚乙烯亚胺-聚乳酸-羟基乙酸纳米粒用于三阴性乳腺癌的靶向治疗。
J Microencapsul. 2022 Jan;39(1):25-36. doi: 10.1080/02652048.2021.2014586. Epub 2021 Dec 20.
2
Pharmacokinetic Comparison between Methotrexate-Loaded Nanoparticles and Nanoemulsions as Hard- and Soft-Type Nanoformulations: A Population Pharmacokinetic Modeling Approach.载甲氨蝶呤纳米颗粒与纳米乳剂作为硬型和软型纳米制剂的药代动力学比较:群体药代动力学建模方法
Pharmaceutics. 2021 Jul 9;13(7):1050. doi: 10.3390/pharmaceutics13071050.
3
用于靶向三阴性乳腺癌治疗的小干扰RNA药物递送策略的进展
Bioengineering (Basel). 2024 Aug 14;11(8):830. doi: 10.3390/bioengineering11080830.
Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More.
乳腺癌免疫治疗的最新进展:肿瘤微环境、纳米技术及其他
Front Bioeng Biotechnol. 2021 Jun 2;9:680315. doi: 10.3389/fbioe.2021.680315. eCollection 2021.
4
The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors.PI3K抑制在乳腺癌治疗中的作用,单独使用或与免疫检查点抑制剂联合使用。
Front Mol Biosci. 2021 May 7;8:648663. doi: 10.3389/fmolb.2021.648663. eCollection 2021.
5
CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer.基于CRISPR/Cas9的基因组编辑用于三阴性乳腺癌的靶向转录调控
Comput Struct Biotechnol J. 2021 Apr 18;19:2384-2397. doi: 10.1016/j.csbj.2021.04.036. eCollection 2021.
6
Triple-negative breast cancer: A run-through of features, classification and current therapies.三阴性乳腺癌:特征、分类及当前治疗方法概述
Oncol Lett. 2021 Jul;22(1):512. doi: 10.3892/ol.2021.12773. Epub 2021 May 5.
7
Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.靶向聚合物纳米颗粒递药系统用于治疗乏氧三阴性乳腺癌
ACS Appl Bio Mater. 2021 Feb 15;4(2):1450-1460. doi: 10.1021/acsabm.0c01336. Epub 2020 Dec 23.
8
Bioactive nanotherapeutic trends to combat triple negative breast cancer.用于对抗三阴性乳腺癌的生物活性纳米治疗趋势。
Bioact Mater. 2021 Mar 13;6(10):3269-3287. doi: 10.1016/j.bioactmat.2021.02.037. eCollection 2021 Oct.
9
Bio-Inspired and Smart Nanoparticles for Triple Negative Breast Cancer Microenvironment.用于三阴性乳腺癌微环境的仿生智能纳米颗粒
Pharmaceutics. 2021 Feb 22;13(2):287. doi: 10.3390/pharmaceutics13020287.
10
Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles.利用氧化还原纳米颗粒控制三阴性乳腺癌的肿瘤生长和血管生成。
Biomaterials. 2021 Feb;269:120645. doi: 10.1016/j.biomaterials.2020.120645. Epub 2021 Jan 6.